Studie zu ALV-100 zur Bewertung von Sicherheit, Verträglichkeit und PK/PD bei übergewichtigen/adipösen Teilnehmern mit oder ohne T2D
Eine Phase-1b-, randomisierte, doppelblinde, placebokontrollierte, Dosis-Eskalations-Studie zur Bewertung von Sicherheit, Verträglichkeit, Pharmakokinetik und Pharmakodynamik von ALV-100 bei Teilnehmern mit Übergewicht oder Adipositas mit oder ohne Typ-2-Diabetes
A Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants with or without Type 2 Diabetes
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 1
Kontakte und Standorte
Studienorte
-
-
Florida
-
Miami, Florida, Vereinigte Staaten, 33172
- Clinical Pharmacology of Miami
-
-
Ohio
-
Columbus, Ohio, Vereinigte Staaten, 43212
- Ohio Clinical Trials
-
-
Texas
-
San Antonio, Texas, Vereinigte Staaten, 78240
- Endeavor Clinical Trials
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
For Part A and B
- Adult male and female participants, aged 18 to 65 years, inclusive, at the time of signing the informed consent form
- Body mass index between 27.0 to 39.9 kg/m2 at Screening, both inclusive; overweight should be due to excess adipose tissue, as judged by the Investigator.
- Have a stable body weight (< 5.0 kg/11 lbs self-reported change) within 90 days prior to Screening
- Females must be surgically sterile (by means of bilateral salpingectomy, hysterectomy or bilateral oophorectomy) or be post-menopausal (defined as spontaneous cessation of menses for at least 1 year prior to Screening). Females who are post-menopausal and < 55 years must have a follicle-stimulating hormone level > 40 IU/L at Screening.
- Males with female partners of child-bearing potential must be willing to practice abstinence or must agree to use condom as contraception throughout the duration of the study. This criterion may be waived for male participants who have had a documented successful vasectomy > 6 months before signing the ICF.
For Part B only
- Diagnosis of Type 2 Diabetes for at least 180 days prior to Screening.
- Glycemic control managed by diet and exercise alone or by stable treatment with metformin and/or sodium-glucose cotransporter 2 inhibitors (SGLT-2i), with no dose changes within 3 months prior to Screening.
- Hemoglobin A1c (HbA1c) between 6.5 % and 9.0% (equivalent to 48-75 mmol/mol), both inclusive, at Screening.
Exclusion Criteria:
For Part A and B
- History or presence of any clinically relevant respiratory, metabolic (including dyslipidemia, however screening total cholesterol below or equal to 302 mg/dL (7.8 mmol/L) and/or screening triglyceride below or equal to 500 mg/dL (5.65 mmol/L) is accepted), renal, hepatic, gastrointestinal, endocrinological conditions (except conditions associated with type 2 diabetes in Part B) at the discretion of the Investigator.
- Participants with a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 or a personal history of nonfamilial medullary thyroid carcinoma.
- Current or history of chronic or acute pancreatitis.
- Obesity caused by known endocrinologic disorders (e.g., Cushing syndrome) or monogenetic or syndromic forms of obesity (for example, Melanocortin 4 Receptor deficiency or Prader Willi Syndrome).
- History of major depressive disorder or other severe psychiatric disorder (for example, schizophrenia, bipolar disorder, or anxiety disorder).
- Lifetime history of a suicide attempt or of any suicidal behavior by endorsement of (answered yes to) any of the items in the suicidal behavior section on the Columbia Suicide Severity Rating Scale (C-SSRS) at Screening.
- Systolic blood pressure ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg at Screening.
- History of or current cardiovascular disease, including but not limited to stable and unstable angina, myocardial infarction, congestive heart failure, transient ischemic attack, stroke, clinically significant arrhythmias and conduction disorders or venous thromboembolism.
Part A only
• History or clinical evidence of Type 1 or Type 2 diabetes mellitus, including HbA1c ≥ 6.5% and/or a fasting plasma glucose (FPG) ≥ 126 mg/dL (7.0 mmol/L) at Screening (female participants with a history of gestational diabetes are allowed).
Part B only
- Fasting plasma glucose (FPG) > 270 mg/dL (15.0 mmol/L) at Screening.
- Proliferative retinopathy or maculopathy as judged by the investigator based on a recent (within1.5 years from Screening) ophthalmologic examination.
- Severe neuropathy as judged by the investigator.
- Advanced nephropathy (defined as albuminuria ≥ 300 mg/g).
- History of severe hypoglycemia or hypoglycemic unawareness as judged by the investigator.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Sequenzielle Zuweisung
- Maskierung: Vervierfachen
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Part A - Cohort 1 (ALV-100)
Participants with overweight or obesity without type 2 diabetes will receive ascending doses of ALV-100 by subcutaneous injection. |
Participants will receive multiple ascending doses of ALV-100. |
|
Placebo-Komparator: Part A - Cohort 1 (Placebo)
Participants with overweight or obesity without type 2 diabetes will receive placebo by subcutaneous injection. |
Participants will receive placebo matching ALV-100, volume-matched to active dose. |
|
Experimental: Part A - Cohort 2 (ALV-100)
Participants with overweight or obesity without type 2 diabetes will receive ascending doses of ALV-100 by subcutaneous injection. |
Participants will receive multiple ascending doses of ALV-100. |
|
Placebo-Komparator: Part A - Cohort 2 (Placebo)
Participants with overweight or obesity without type 2 diabetes will receive placebo by subcutaneous injection. |
Participants will receive placebo matching ALV-100, volume-matched to active dose. |
|
Experimental: Part A - Cohort 3 (ALV-100)
Participants with overweight or obesity without type 2 diabetes will receive ascending doses of ALV-100 by subcutaneous injection. |
Participants will receive multiple ascending doses of ALV-100. |
|
Placebo-Komparator: Part A - Cohort 3 (Placebo)
Participants with overweight or obesity without type 2 diabetes will receive placebo by subcutaneous injection. |
Participants will receive placebo matching ALV-100, volume-matched to active dose. |
|
Experimental: Part A - Cohort 4 (ALV-100)
Participants with overweight or obesity without type 2 diabetes will receive ascending doses of ALV-100 by subcutaneous injection. |
Participants will receive multiple ascending doses of ALV-100. |
|
Placebo-Komparator: Part A - Cohort 4 (Placebo)
Participants with overweight or obesity without type 2 diabetes will receive placebo by subcutaneous injection. |
Participants will receive placebo matching ALV-100, volume-matched to active dose. |
|
Experimental: Part B - T2D Cohort (ALV-100)
Participants with overweight or obesity with type 2 diabetes will receive ascending doses of ALV-100 by subcutaneous injection. |
Participants will receive multiple ascending doses of ALV-100. |
|
Placebo-Komparator: Part B - T2D Cohort (Placebo)
Participants with overweight or obesity with type 2 diabetes will receive placebo by subcutaneous injection. |
Participants will receive placebo matching ALV-100, volume-matched to active dose. |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Safety and tolerability
Zeitfenster: From First Dose to Week 52
|
Incidence of treatment emergent adverse events (TEAEs) |
From First Dose to Week 52
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Pharmacokinetics (PK) of intact ALV-100 and total ALV-100 - Cmax, MD
Zeitfenster: From First Dose to Week 52
|
Maximum observed serum concentration after multiple doses (MD) (Cmax, MD) |
From First Dose to Week 52
|
|
Pharmacokinetics (PK) of intact ALV-100 and total ALV-100 - AUC(0-τ), MD
Zeitfenster: From First Dose to Week 52
|
Area under the serum concentration-time curve from time zero to τ, where τ is the dosing interval, (AUC(0-τ), MD) |
From First Dose to Week 52
|
|
Pharmacodynamic (PD) impact on body weight
Zeitfenster: Baseline, Week 32 and Week 52
|
Change from baseline in body weight |
Baseline, Week 32 and Week 52
|
|
Pharmacodynamic (PD) impact on body weight percentage
Zeitfenster: Baseline, Week 32 and Week 52
|
Change from baseline in body weight percentage |
Baseline, Week 32 and Week 52
|
|
Immunogenicity
Zeitfenster: From Baseline to Week 52
|
Incidence of Anti-ALV-100 drug antibodies, including assessments of cross-reactivity and neutralizing antibodies. |
From Baseline to Week 52
|
|
Relationship between ALV-100 serum concentration and QTc interval changes (Part A Only)
Zeitfenster: From First Dose to Week 52
|
Measurement of change in individual specific heart rate corrected QT interval (QTcI) and Fridericia heart rate corrected QT interval (QTcF) on 12-lead ECG. |
From First Dose to Week 52
|
|
Paracetamol (acetaminophen) absorption test (PAT) (Part A Only)
Zeitfenster: From First Dose to Week 52
|
Measurement of acetaminophen PK parameters to evaluate the effect of ALV-100 on the gastric emptying rate. |
From First Dose to Week 52
|
|
Pharmacodynamic (PD) impact of ALV-100 on antidiabetic medication (Part B Only)
Zeitfenster: From Baseline to Week 32
|
Change in use of concomitant glucose-lowering medication |
From Baseline to Week 32
|
|
Pharmacodynamic (PD) impact of ALV-100 on glycemic parameters (Part B Only)
Zeitfenster: Week 32 and Week 52
|
Measuring the number of participants achieving target Hemoglobin A1c values |
Week 32 and Week 52
|
|
Hypoglycemic Safety (Part B Only)
Zeitfenster: From Baseline to Week 52
|
Measured by the incidence of symptomatic hypoglycemia, documented symptomatic hypoglycemia and severe hypoglycemia |
From Baseline to Week 52
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Ermittler
Ermittler
- Studienleiter: Karen Tornøe, MD, PhD, Alveus Therapeutics
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des endokrinen Systems
- Ernährungsstörungen
- Stoffwechselerkrankungen
- Überernährung
- Körpergewicht
- Änderungen des Körpergewichts
- Störungen des Glukosestoffwechsels
- Diabetes Mellitus
- Pathologische Zustände, Anzeichen und Symptome
- Ernährungs- und Stoffwechselerkrankungen
- Anzeichen und Symptome
- Übergewicht
- Fettleibigkeit
- Gewichtsverlust
- Diabetes mellitus, Typ 2
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- ALV-102-1
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .